All In Biotech

Drug Trial Radar · NCT07197866

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

May 3, 2029

Study completion May 17, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Conditions

  • Multiple System Atrophy

Interventions

  • TEV-56286Drug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing an adverse eventTime frame: Baseline to Week 100
  2. Number of participants who withdrew from the trial due to an adverse eventTime frame: Baseline to Week 100

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 15554

    La Jolla, California · Recruiting

  • Teva Investigational Site 15544

    Boca Raton, Florida · Recruiting

  • Teva Investigational Site 15555

    Tampa, Florida · Recruiting

  • Teva Investigational Site 15550

    Chicago, Illinois · Recruiting

  • Teva Investigational Site 15546

    Kansas City, Kansas · Recruiting

  • Teva Investigational Site 15549

    New York, New York · Recruiting

  • Teva Investigational Site 15551

    New York, New York · Recruiting

  • Teva Investigational Site 15553

    Durham, North Carolina · Recruiting

  • Teva Investigational Site 15548

    Pittsburgh, Pennsylvania · Recruiting

  • Teva Investigational Site 15543

    Spokane, Washington · Recruiting

  • Teva Investigational Site 35290

    Bordeaux, France · Recruiting

  • Teva Investigational Site 35289

    Marseille, France · Recruiting

  • Teva Investigational Site 35291

    Paris, France · Recruiting

  • Teva Investigational Site 35292

    Toulouse, France · Recruiting

  • Teva Investigational Site 32818

    Dresden, Germany · Recruiting

  • Teva Investigational Site 32822

    Düsseldorf, Germany · Recruiting

  • Teva Investigational Site 32825

    Kassel, Germany · Recruiting

  • Teva Investigational Site 32824

    Marburg, Germany · Recruiting

  • Teva Investigational Site 32820

    München, Germany · Recruiting

  • Teva Investigational Site 32819

    Münster, Germany · Recruiting

  • Teva Investigational Site 80203

    Haifa, Israel · Recruiting

  • Teva Investigational Site 80204

    Tel Aviv, Israel · Recruiting

  • Teva Investigational Site 30299

    Bologna, Italy · Recruiting

  • Teva Investigational Site 30297

    Catania, Italy · Recruiting

  • Teva Investigational Site 30298

    Milan, Italy · Recruiting

  • Teva Investigational Site 30294

    Padova, Italy · Recruiting

  • Teva Investigational Site 30296

    Roma, Italy · Recruiting

  • Teva Investigational Site 30295

    Salerno, Italy · Recruiting

  • Teva Investigational Site 84140

    Chiba, Japan · Recruiting

  • Teva Investigational Site 84139

    Fuchū, Japan · Recruiting

  • Teva Investigational Site 84137

    Niigata, Japan · Recruiting

  • Teva Investigational Site 84138

    Sagamihara, Japan · Recruiting

  • Teva Investigational Site 84141

    Sanda-shi, Japan · Recruiting

  • Teva Investigational Site 84135

    Sendai, Japan · Recruiting

  • Teva Investigational Site 31324

    Barcelona, Spain · Recruiting

  • Teva Investigational Site 31323

    Barcelona, Spain · Recruiting

  • Teva Investigational Site 31321

    Barcelona, Spain · Recruiting

  • Teva Investigational Site 31327

    Madrid, Spain · Recruiting

  • Teva Investigational Site 31320

    Pamplona, Spain · Recruiting

  • Teva Investigational Site 31322

    Seville, Spain · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.